Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. The ...

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.

GLP-1 receptor agonists are associated with risk reductions for dozens of diseases and conditions in addition to rapid weight ...

An experimental once-daily pill to treat obesity can help people lose a significant amount of weight, according to new data ...

Eli Lilly and Company (LLY), one of the world’s leading pharmaceutical giants, might have just unveiled its next major growth catalyst — one that could significantly bolster its dominant position in ...

President William Ruto appointed a technical team to evaluate the performance of the UDA and ODM partnership five months ...